We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year. 
days to go: Expired investment: £251,600
Doctors available 24 hours a day, 365 days a year to visit, diagnose, treat, refer and prescribe medication as needed. No membership fees or hidden costs.
days to go: Expired investment: £540,695
Providing convenient and affordable healthcare to patients either at home or their workplace. Practitioners can visit patients and offer a range of medical treatments including vaccinations, testing, physiotherapy and primary care. Qured have been highly successful in London and are growing at an alarming rate, ready to help the whole of the UK.
days to go: Expired investment: £763,160
Molecular Warehouse are trying to create a world where most diseases are prevented by giving people the chance to monitor and manage their health where ever and whenever. Molecular Warehouse have developed a platform that allows anyone to test themselves at any time.
days to go: Expired investment: £737,480
Carbon Gold (CG) is an organic biochar producer and retailer. It claims that its products can replace harmful pesticides, last longer, and lock away CO2. The company's sales increased by 253% from £77,000 to £272,000 in 2020 with sales in 17 countries worldwide. CG's organic products employ biochar, a type of charcoal made from sustainably sourced materials. CG further enriches it with multiple strains of fungi, bacteria and minerals, that support healthy soil biology. The company is partnering with the Woodland Trust, is certified by the Soil Association, and is also a certified B Corp. The company will use the investment to boost its marketing, international development, and manufacturing.

Pitch Rated

83%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £722,468
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.

Pitch Rated

48%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £691,497
FreeHand is a robotic surgical camera controller that aims to make surgeries precise and safer. The company cites data arguing that over 15 million keyhole surgeries are performed annually in which an additional clinician is mostly required to manually hold the camera the surgeon uses to see the operating field. The company asserts that this is not the most optimal way. FreeHand's robotic camera controller aims to solve this issue by providing steady images and precise control, saving time, and improving outcomes. The company has regulatory clearance for sale in the EU, US, and Japan. FreeHand points out that surgical robotics is one of the fastest-growing segments in Medical Technology, projected to reach $91.5 billion by 2025. It aims to become a contender in this segment. FreeHand claims that surgeons have successfully used its robotic controller in more than 15,000 procedures. The company will use the investment to expand the distributor base in Europe, Asia and Latin America, targeting over 12 million procedures annually.
days to go: Expired investment: £1,003,350
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go: Expired investment: £250,000
Pawprint is a behavioural change platform that is on a mission to fight climate change. The platform allows people to measure, understand and reduce their carbon footprint, and fight ‘climate change’ by giving people bite-sized chunks to focus on. It aims to be the middleman, helping brands reach and understand their audience by offering these brands personalised challenges to help their reduce carbon footprint. The market for behavioural change platforms is slowly gaining solid traction with established brands such as Fitbit, Strava, and Calm. Pawprint aims to capitalise on this collective concern and deliver services that help mitigate those concerns.

Pitch Rated

43%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £352,440
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph